Behind Mark53 lies a Vienna-based company that was founded at the start of 2013. The company’s strategic direction lies in making a precise, standardised p53 gene test available in the form of the Mark53® analysis, which established the prerequisites for the routine clinical application of the predictive biomarker.
The assumption is that the p53 gene can be employed as a predictive marker, based upon clinical studies conducted at the Medical University of Vienna , headed by Univ. Prof. Dr. Daniela Kandioler. In these studies, the connection between the response to a standard chemotherapy and the p53 gene status were examined in different cancer types.
c/o Univ.Prof.Dr. Daniela Kandioler
T +43 (0)664 94 70 290
F +43 (0)1 2533033 5540
UniCredit Bank Austria AG
Austria: Konto-Nr. 10001153526, BLZ 12000
International: IBAN AT931200010001153526, BIC BKAUATWW
VAT No. ATU67679915
Vienna Chamber of Commerce, FN 391098w